In vivo and in vitro studies showed that increasing miR-23a-5p levels could reduce the inflammatory and oxidative processes involved in COPD, specifically by targeting RAGE [41], and its anti-inflammatory effect might be absent in COPD, considering the low expression levels of miRNA in patients compared with the control group [41]. The gene discussed is AGER; the disease is chronic obstructive pulmonary disease.